{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:19:20Z","timestamp":1793992760157,"version":"4.8.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We have recently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in patients with extensive treatment-refractory mesothelioma. These unprecedented tumor responses have prompted us to review how mesothelin was discovered and the advances that led to these tumor responses. This review is not comprehensive but focuses on major developments over the past 20 years since mesothelin was first identified in our laboratory. Mesothelin is a cell-surface glycoprotein whose expression in normal human tissues is restricted to mesothelial cells. Because it is highly expressed by many solid tumors, it is an attractive immunotherapy target. Antibody-based therapies currently in clinical trials include an immunotoxin, a chimeric monoclonal antibody, and an antibody drug conjugate. In addition, a mesothelin tumor vaccine and a mesothelin- chimeric antigen receptor are being evaluated in the clinic. SS1P, an anti-mesothelin immunotoxin, was the first mesothelin-directed therapy to enter the clinic, and its use showed that mesothelin-targeted therapy was safe in patients. More importantly, our recent work has shown that SS1P in combination with pentostatin and cyclophosphamide can result in durable tumor regression in patients with advanced mesothelioma and opens up the possibility that such an approach can benefit patients with many common cancers. Cancer Res; 74(11); 2907\u201312. \u00a92014 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-14-0337","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T23:11:44Z","timestamp":1400022704000},"page":"2907-2912","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy"],"prefix":"10.1158","volume":"74","author":[{"given":"Ira","family":"Pastan","sequence":"first","affiliation":[{"name":"Authors' Affiliation: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"Authors' Affiliation: Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2014,5,29]]},"reference":[{"key":"2022061705005800500_bib1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"2022061705005800500_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000478-199203000-00006","article-title":"Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma","volume":"16","author":"Chang","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"2022061705005800500_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.2910510408","article-title":"Frequent expression of the tumor antigen CAK1 in squamous-cell carcinoma","volume":"51","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"2022061705005800500_bib4","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"1993","journal-title":"Am J Surg Pathol"},{"key":"2022061705005800500_bib5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"2022061705005800500_bib6","first-page":"3862","article-title":"Mesothelin is over-expressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022061705005800500_bib8","doi-asserted-by":"crossref","first-page":"11960","DOI":"10.1074\/jbc.M110.193458","article-title":"Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in in cancers","volume":"286","author":"Ren","year":"2011","journal-title":"J Biol Chem"},{"key":"2022061705005800500_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061705005800500_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0021-9258(17)42180-6","article-title":"A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5","volume":"269","author":"Yamaguchi","year":"1994","journal-title":"J Biol Chem"},{"key":"2022061705005800500_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<559::AID-IJC13>3.0.CO;2-Y","article-title":"111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenografts expressing mesothelin","volume":"80","author":"Hassan","year":"1999","journal-title":"Int J Cancer"},{"key":"2022061705005800500_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002371-200007000-00011","article-title":"Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma","volume":"23","author":"Hassan","year":"2000","journal-title":"J Immunother"},{"key":"2022061705005800500_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061705005800500_bib14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/9872","article-title":"Improving antibody affinity by mimicking somatic hypermutation in vitro","volume":"17","author":"Chowdhury","year":"1999","journal-title":"Nat Biotech"},{"key":"2022061705005800500_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2022061705005800500_bib16","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","article-title":"Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma","volume":"96","author":"Scholler","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061705005800500_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1055-9965.EPI-06-0479","article-title":"Mesothelin is shed from tumor cells","volume":"15","author":"Ho","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061705005800500_bib19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"2022061705005800500_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/cclm.2011.816","article-title":"Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers","volume":"50","author":"Sharon","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2022061705005800500_bib21","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib22","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1158\/0008-5472.CAN-11-0466","article-title":"Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"key":"2022061705005800500_bib23","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2022061705005800500_bib24","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"2022061705005800500_bib25","first-page":"20","article-title":"Preclinical evaluation of MORAb-09, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun"},{"key":"2022061705005800500_bib26","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2009.07.016","article-title":"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy","volume":"68","author":"Hassan","year":"2010","journal-title":"Lung Cancer"},{"key":"2022061705005800500_bib27","first-page":"185","article-title":"Suppression of cell death by the secretory form of N-terminal ERC\/mesothelin","volume":"26","author":"Wang","year":"2010","journal-title":"Int J Mol Med"},{"key":"2022061705005800500_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1756-9966-31-84","article-title":"Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and \u2013independent signal pathway","volume":"31","author":"Zheng","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"2022061705005800500_bib29","first-page":"5151","article-title":"Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P","volume":"32","author":"Zhang","year":"2012","journal-title":"Anticancer Res"},{"key":"2022061705005800500_bib30","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib31","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib32","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase 1 trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib33","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","article-title":"Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.7026","article-title":"Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response","volume":"29","author":"Hassan","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061705005800500_bib35","first-page":"345","article-title":"Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial","volume":"9","author":"Oratz","year":"1990","journal-title":"J Biol Response Mod"},{"key":"2022061705005800500_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002371-199304000-00007","article-title":"Phase I\/II study of murine monoclonal antibody-ricin A chain (xomazyme-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma","volume":"13","author":"Selvaggi","year":"1993","journal-title":"J Immunother"},{"key":"2022061705005800500_bib37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1078-0432.CCR-1160-3","article-title":"Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib38","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1158\/1078-0432.CCR-11-0493","article-title":"Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts","volume":"17","author":"Mossoba","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib39","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"2022061705005800500_bib40","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib41"},{"key":"2022061705005800500_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7030","article-title":"Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multicenter phase II clinical trial","volume":"30","author":"Hassan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022061705005800500_bib43","article-title":"First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94\u20139343, in patients with advanced solid tumors [abstract]","volume-title":"In: Proceedings of the AACR 104th Annual Meeting; 2013 Apr 6-10","author":"Bendell"},{"key":"2022061705005800500_bib44"},{"key":"2022061705005800500_bib45"},{"key":"2022061705005800500_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2022061705005800500_bib47","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2022061705005800500_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.3_suppl.177","article-title":"A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: updated results","volume":"32","author":"Le","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022061705005800500_bib49","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.1073\/pnas.1209292109","article-title":"Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes","volume":"109","author":"Liu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061705005800500_bib50","doi-asserted-by":"crossref","first-page":"E3597","DOI":"10.1073\/pnas.1218138109","article-title":"Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"109","author":"Mazor","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/11\/2907\/2702971\/2907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/74\/11\/2907\/2702971\/2907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:40:30Z","timestamp":1655466030000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/74\/11\/2907\/592751\/Discovery-of-Mesothelin-and-Exploiting-It-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,29]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,5,29]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-14-0337","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,29]]}}}